Isosorbide Mononitrate Tablet Market Report 2026 Market Outlook Supported By A Forecast 5.3% CAGR

The pharmaceutical landscape for cardiovascular treatments is evolving rapidly, with particular attention on medications that improve patient outcomes and convenience. One such area gaining momentum is the isosorbide mononitrate tablet market, which is witnessing promising growth driven by advances in drug formulations and expanded access to treatments. Below, we explore the market's size, key players, emerging trends, and the segmentation that defines this sector.

Projected Expansion of the Isosorbide Mononitrate Tablet Market by 2030
The market for isosorbide mononitrate tablets is poised for significant growth in the coming years. By 2030, it is anticipated to reach a valuation of $1.55 billion, expanding at a compound annual growth rate (CAGR) of 5.3%. This positive outlook is fueled by several factors, including the rising incidence of chronic cardiovascular diseases, growing preference for extended-release tablet formulations, increased utilization of online pharmacy platforms, enhanced diagnostic capabilities for angina and heart failure, and broader availability of cardiovascular medications in emerging economies. Notable trends during this timeframe encompass the development of long-acting maintenance therapies, greater adoption of generic nitrate drugs, improved patient adherence through once-daily dosing, and the expansion of pharmacy distribution channels both online and offline.

The isosorbide mononitrate tablet market size has grown strongly in recent years. It will grow from $1.2 billion in 2025 to $1.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, long-term use of nitrates in angina management, increasing aging population, availability of cost-effective generic drugs, expansion of hospital and retail pharmacy infrastructure.

Download a free sample of the isosorbide mononitrate tablet market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24268&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving the Isosorbide Mononitrate Tablet Market
The competitive landscape of the isosorbide mononitrate tablet sector features numerous influential pharmaceutical companies. These key market participants include Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Micro Labs Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Sandoz International GmbH, Qilu Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group, and Shandong Keyuan Pharmaceutical Co., Ltd.

Emerging Developments Shaping the Isosorbide Mononitrate Tablet Market
Pharmaceutical companies are prioritizing innovation by focusing on extended-release (ER) formulations designed to improve patient compliance and sustain therapeutic effects. Extended-release tablets enable a gradual medication release over time, decreasing the frequency of doses and maintaining stable drug levels in the bloodstream. This approach enhances treatment outcomes for conditions like angina pectoris. For example, in February 2024, Zydus Lifesciences Limited, an India-based drug manufacturer, received approval from the United States Food and Drug Administration (USFDA) to produce and market isosorbide mononitrate extended-release tablets in dosages of 30 mg, 60 mg, and 120 mg. These tablets help prevent chest pain in patients with coronary artery disease and are bioequivalent to the reference listed drug, Imdur extended-release tablets.

View the full isosorbide mononitrate tablet market report:
https://www.thebusinessresearchcompany.com/report/isosorbide-mononitrate-tablet-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Segment Breakdown of the Isosorbide Mononitrate Tablet Market
The isosorbide mononitrate tablet market can be classified broadly into several segments for better analysis:
1) Dosage Form: Immediate-Release Tablets and Extended-Release Tablets
2) Indication Type: Angina Pectoris and Coronary Artery Disease (CAD)
3) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Further subcategories include:
- Immediate-Release Tablets: Low-Dose and Single Strength Tablets
- Extended-Release Tablets: Moderate-Dose, High-Dose, Once-Daily Formulations, and Twice-Daily Formulations

This segmentation framework helps in understanding varying patient needs and market dynamics, guiding industry stakeholders in targeting their product development and distribution strategies effectively.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.